Infective endocarditis remains an uncommon disease thus any individual doctor's experience of it must of necessity be limited. Such patients are always "interesting" and invariably stay in hospital for weeks rather than days-this, I think, leads clinicians to assume the infection is more common than it really is. As a (clinical) microbiologist I have been in a unique position to follow all patients with infective endocarditis who have presented or been referred to St Thomas' Hospital in London since 1970. This has provided a wealth of information as well as the background for this article.
Nomenclature
The old Oslerian classification of endocarditis as acute, subacute, or chronic was based on the usual course of untreated disease and it is not appropriate today, yet remarkably "SBE" is still used by countless clinicians as a blanket description of patients with endocarditis even when the patient has been ill for only a few days. I know this from perusal of blood culture request forms. The preferred term is infective endocarditis rather than bacterial endocarditis, as fungi at least are outside the latter definition. Native valve infection should be distinguished from prosthetic. Prosthetic endocarditis has conventionally been divided into early and late onset after surgery, with 60 days as the cut off point. This is an unsatisfactory division implying, as it does, that infections acquired at the time of the valve replacement will become manifest within this time whereas it is known that some will not present until much later. A limit of a year has been proposed and this is more realistic. As important as any time limit is the pathogenesis of the infection, whether it has been acquired in the community or as result of a hospital procedure or operation. practical. Compliance is said to be improving but is still far from universal. There is also a depressing number of clinicians who institute a "personalised" version of prophylaxis for their patients that is often inappropriate.
How long to treat endocarditis? Even though it was shown many years ago in carefully monitored clinical trials that penicillin sensitive viridans streptococcal native valve endocarditis can be satisfactorily treated with a two week regimen of penicillin (oral, intramuscular, or intravenous) plus an aminoglycoside,89 this important information seems to have been largely ignored and there is an entrenched belief that six weeks of therapy is needed. Such practice is unacceptable and is inconvenient for patient and hospital alike. Lengthy courses of (usually) very large parenteral doses of penicillin are likely to result in toxicity with fevers, neutropenia, and other ill effects. Failure to respond to antibiotic treatment almost always means that a cardiac surgeon is needed, not an increased dose or change (or both) of antibiotic. Very few cases of infective endocarditis require more than four weeks of antibiotic treatment, and many require less.
Microbiological monitoring of antibiotic treatment It is commonly believed in microbiological circles that a full in vitro investigation of the causative microbe (minimum inhibitory and bactericidal concentrations, synergy studies, etc) is mandatory to select an appropriate regimen for all patients with infective endocarditis. For most organisms a routine disc sensitivity is entirely satisfactory and has the merit of being available soon after the organism is isolated from the blood culture. In vitro tests take time and are not routinely done in many laboratories, therefore, they may well give erroneous results, and in most cases contribute little. In practice it is not difficult to select an appropriate regimen for most patients with infective endocarditis. The other microbiological sacred cow is the serum bactericidal titre (back titrations). This has no correlation with clinical cure. For years I used assiduously to perform these tests and "fine tune" the antibiotic therapy accordingly, I have now concluded that it is better to assess the clinical response rather than that of an organism in a test tube.
Culture negative endocarditis Cases of infective endocarditis where neither blood culture, excised valve culture, or serology demonstrate a causative pathogen are uncommon, perhaps as few as 5% of cases. Probably the most common explanation is previous antibiotic treatment that, even if it has not sterilised the valve, will have sterilised the blood cultures. Such cases are most likely to have been caused by viridans streptococci. All patients with infective endocarditis whose blood cultures are sterile should have serological investigations for organisms that cannot readily be isolated by conventional culture methods such as Coxiella burnetii, Chlamydia spp and the recently recognised Bartonella (previously Rochalimaea) spp, which incidentally give serological cross reactions with Chlamydia spp.10
In conclusion, it is important to emphasise that the greatest advances in the successful management of infective endocarditis since the advent of penicillin have come from cardiology and cardiac surgery. Remarkably, some hospital clinicians are still reluctant to refer patients for specialist care; this is quite unacceptable. As we approach the millennium it would be gratifying if the UK guidelines on prophylaxis and treatment (to which the BSAC working party devote much time) could be followed by more doctors. Rudolph Karl Virchow was a great pathologist whose worldwide fame was first established by his concept that cells are the basic unit of life and that a study of cell changes must be the cornerstone of pathology. He pioneered the use of the microscope for this purpose and wrote an acclaimed book Die Cellularpathologie.
Virchow was the first to realise and prove that clots in pulmonary arteries had not been formed there but came from leg and pelvic veins. He noted that the symptoms of pulmonary embolism ranged from sudden death to silent emboli and he related these to the pathological findings. He produced experimental emboli in the dog and later showed that phlebitis was a mechanical and not, as was then thought, an infective process. The terms "embolism" and "thrombosis" were invented by him to describe these processes. Virchow's triad identifies the three main causes of venous thrombosis. He 
